ERn Financial LLC’s Decoy Therapeutics DCOY Stock Holding History

ERn Financial LLC’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	-$6K	–	175
2022 Q3	$6K	Hold	1	–	–	﹤0.01%	159
2022 Q2	$7K	Buy	+1	New	+$8.63K	﹤0.01%	164

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ERn Financial LLC's DCOY Position: Q4 2022 in Review

ERn Financial LLC sold out of Decoy Therapeutics (DCOY) in Q4 2022, closing a stake of 1 share — an estimated $6K sold.

ERn Financial LLC first reported a position in DCOY in Q2 2022 and held it in 2 quarters. The position peaked at $7K in Q2 2022. 4 funds tracked by Wall St. Rank hold DCOY as of Q4 2022.

ERn Financial LLC reported no remaining Decoy Therapeutics position as of Q4 2022 after selling out during the quarter.
ERn Financial LLC sold 1 Decoy Therapeutics share in Q4 2022, an estimated $6K.
ERn Financial LLC first reported a position in Decoy Therapeutics in Q2 2022 and held it in 2 quarters.
ERn Financial LLC's Decoy Therapeutics position peaked at $7K in Q2 2022.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2022.

Based on ERn Financial LLC's 13F filing for Q4 2022, filed 14 Feb 2023.